Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Articles

Vol. 2 No. 1 (2011): January – March 2011

Quantitative Structure Activity Relationship Analysis of Benzimidazole Derivatives as Aldose Reductase Inhibitors

DOI
https://doi.org/10.37285/ijddd.2.1.10
Submitted
November 28, 2024
Published
2024-12-08

Abstract

Hyperglycemia is involved in the pathogenesis of diabetic neuropathy, retinopathy, nephropathy, and macro-vascular disease via multiple mechanisms, of which increased aldose reductase activity. Aldose reductase inhibitors, when administered from the onset of hyperglycemia, prevent the progression of polyol accumulation–linked complication. In this work, we report quantitative structure activity relationship analysis performed on the Triazino[4,3-α]benzimidazole acetic acid derivatives as aldose reductase inhibitors. The molecular modeling study was performed by using the software BioMed CAChe 6.0 and the regression analysis by SYSTAT 10.2. Various physicochemical parameters belonging to different classes viz. hydrophobic, steric and electronic etc. were calculated. QSAR models were generated using 17 compounds. The model showed a good correlative and predictive ability having convention coefficient (r2) of 0.846 and cross-validated correlation coefficient (q2) of 0.6866 by LOO external validation method. Based on the developed QSAR model, it may be concluded that aldose reductase inhibition activity of benzimidazole acetic acid derivatives is strongly influenced by the thermodynamic and electronic nature of the substituents. QSAR model shows that LOGP, LUMO energy, and steric energy are negatively affecting the biological activity. For a molecule to have higher aldose reductase activity, compound should be less lipophilic and should have more electronegative groups or atoms than electropositive groups or atoms present in the compound.

References

  1. [1] Maccari, R.; Ottana, R.; Ciurleo, R.; Vigorita, M.G.; Rakowitz, D; Steindl, T.; Langer, T. Bioorg. Med. Chem. 2007, 17, 3886-3893.
  2. [2] Alexiou, P.; Nicolaou, I.; Stefek, M.; Kristl, A.; Demopoulos, V.J. Bioorg. Med. Chem. 2008, 16, 3926-3932.
  3. [3] Van-Zandt, M.C.; Sibley E.O.; McCann, E.E.; Combs,K. J.; Flam, B.; Sawicki, D.R.; Sabetta, A.; Carrington, A.; Sredy, J.; Howard, E.; Mitschler, A.; Podjarny, A.D. Bioorg. Med. Chem. 2004, 12, 5661-5675.
  4. [4] Da Settimo, F.; Primofiore, G.; La Motta, C.; Salerno, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Laneri, S,; Boldrini, E. Bioorg. Med. Chem. 2005, 13, 491-499.
  5. [5] Oates, P.J.; Mylari, B.L. Expert Opin. Investig. Drugs 1999, 8, 2095–2119.
  6. [6] Obrosova, I.G.; Van Huysen, C.; Fathallah, L.; Cao, X.C.; Greene, D.A.; Stevens, M.J. FASEB J. 2002, 16, 123–125.
  7. [7] Kato, N.; Yashima, S.; Suzuki, T.; Nakayama, Y.; Jomori, T. J. Diab. Compl. 2003, 17, 374 –379.
  8. [8] Thornalley, P.J. Int. Rev. Neurobiol. 2002, 50, 37–57.
  9. [9] Vlassara, H.; Palace, M.R. Mt. Sinai J. Med. 2003,70, 232–241.
  10. [10] Nakamura, J.; Kato, K.; Hamada, Y.; Nakayama, M.; Chaya, S.; Nakashima, E.; Naruse, K.; Kasuy, Y.; Mizubayashi, R.; Miwa, K.; Yasuda, Y.; Kamiya, H.; Ienaga, K.; Sakakibara, F.; Koh, N.; Hotta, N. Diabetes 1999, 48, 2090-2095.
  11. [11] Way, K.J.; Katai, N.; King, G.L. Diabet. Med. 2001,18,945-959.
  12. [12] Obrosova, I.G.; Int. Rev. Neurobiol. 2002, 50, 3–35.
  13. [13] Pennathur, S.; Heinecke, J.W. Front Biosci. 2004, 9, 565–574.
  14. [14] Lou, M.F.; Dickerson, J.E.; Jr Garadi, R.; York, B.M. Exp Eye Res. 1998,46,517–530.
  15. [15] Obrosova, I.G.; Fathallah, L. Diabetologia 2000,43,1048–1055.
  16. [16] Lowitt, S.; Malone, J.I.; Salem, A.F.; Korthals, J.; Benford, S. Metabolism 1995, 44, 677– 680.
  17. [17] Obrosova, I.G.; Minchenko, A.G.; Vasupuram, R.; White, L.; Abatan, O.I.; Kumagai, A.K.; Frank, R.N.; Stevens,M. J. Diabetes 2003,52,864–871.
  18. [18] El-Remessy, A.B.; Abou-Mohamed, G.; Caldwell, R.W.; Caldwell, R.B. Invest Ophthalmol. Vis. Sci. 2003,44,3135–3143.
  19. [19] Inoue, J.; Cui,Y. S.; Sakai, O.; Nakamura, Y.; Kogiso, H.; Peter F.; Kador, P. F. Bioorg. Med. Chem. 2000, 8, 2167-2173.
  20. [20] Donkora, I. O.; Ghanyb, Y. S. A.; Kadorc, P. F.; Mizoguchic, T.; Malikc, A. B.; Millera, D. D. Eur. J. Med. Chem. 1998,33, 15-22.
  21. [21] Costantino, L.; Corso, A. D.; Rastelli, G.; Petrash, J. M.; Mura, U. Eur. J. Med. Chem. 2001, 36, 697-703.
  22. [22] Rakowitz, D.; Maccari, R.; Ottana, R.; Vigorita, M. G. Bioorg. Med. Chem. 2006,14, 567-574.
  23. [23] Settimo, A. D.; Primofiore, G.; Settimo, F. D.; Simorini, F.; Motta, C. L.; Martinelli, A.; Boldrini, E. Eur. J. Med. Chem. 1996, 31, 49-58.
  24. [24] Maccari, R.; Ottana, R.; Ciurleo, R.; Vigorita, M. V.; Rakowitz, D.; Steindl, T.; Langer, T. Bioorg. Med. Chem.Lett. 2007,17, 3886-3893.
  25. [25] Da Settimo, F.; Primofiore, G.; Da Settimo, A.; La Motta, C.; Taliani, S.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrini, E. J. Med. Chem. 2001, 44, 4359-4369.
  26. [26] Oprea, T. J.; Waller, G. L.; Marshall, G. R. J. Med. Chem. 1994, 37, 2206-2215.
  27. [27] www.cache.fujitsu.com/biomedcache/index.shtml.
  28. [28] SYSTAT Software 10.2 for Windows. SYSTAT Software, Inc.2002, Richmond, California.